Release reagent for vitamin d compounds
US-2017363649-A1 · Dec 21, 2017 · US
N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs and their uses
US8987235B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8987235-B2 |
| Application number | US-201213473259-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 16, 2012 |
| Priority date | May 17, 2011 |
| Publication date | Mar 24, 2015 |
| Grant date | Mar 24, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention discloses N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1α-hydroxyvitamin D 3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent especially for the treatment or prevention of leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.
First claim
Opening claim text (preview).
We claim: 1. A compound of the formula: where X 1 ,X 2 , and X 3 , are the same or different and are each selected from the group consisting of hydrogen and a hydroxy-protecting group. 2. The compound of claim 1 wherein X 1 is hydrogen. 3. The compound of claim 1 wherein X 1 and X 2 are both t-butyldimethylsilyl.…
Assignees
Inventors
Classifications
- C07C401/00Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8987235B2 cover?
- This invention discloses N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1α-hydroxyvitamin D 3 and pharmaceutical uses therefor. This compound exhibits relatively high binding activity and pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiati…
- Who is the assignee on this patent?
- Deluca Hector F, Clagett-Dame Margaret, Plum Lori A, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07C401/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).